The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Herceptin Biosimilar Market Research Report 2025
Synopsis
Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein.
The global Herceptin Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Herceptin Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Herceptin Biosimilar.
Report Scope
The Herceptin Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Herceptin Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Herceptin Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Biopharma
Biocon
Celltrion
Gedeon Richter
Genor Biopharma
Mabion
Mylan
Roche
The Instituto Vital Brazil
Segment by Type
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Other
Segment by Application
Hospital & Clinics
Oncology Centers
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Herceptin Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Herceptin Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein.
The global Herceptin Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Herceptin Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Herceptin Biosimilar.
Report Scope
The Herceptin Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Herceptin Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Herceptin Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Biopharma
Biocon
Celltrion
Gedeon Richter
Genor Biopharma
Mabion
Mylan
Roche
The Instituto Vital Brazil
Segment by Type
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Other
Segment by Application
Hospital & Clinics
Oncology Centers
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Herceptin Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Herceptin Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Herceptin Biosimilar Market Overview
1.1 Product Overview and Scope of Herceptin Biosimilar
1.2 Herceptin Biosimilar Segment by Type
1.2.1 Global Herceptin Biosimilar Market Value Comparison by Type (2024-2030)
1.2.2 Breast Cancer
1.2.3 Colorectal Cancer
1.2.4 Leukemia
1.2.5 Lymphoma
1.2.6 Other
1.3 Herceptin Biosimilar Segment by Application
1.3.1 Global Herceptin Biosimilar Market Value by Application: (2024-2030)
1.3.2 Hospital & Clinics
1.3.3 Oncology Centers
1.3.4 Other
1.4 Global Herceptin Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Herceptin Biosimilar Revenue 2019-2030
1.4.2 Global Herceptin Biosimilar Sales 2019-2030
1.4.3 Global Herceptin Biosimilar Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Herceptin Biosimilar Market Competition by Manufacturers
2.1 Global Herceptin Biosimilar Sales Market Share by Manufacturers (2019-2024)
2.2 Global Herceptin Biosimilar Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Herceptin Biosimilar Average Price by Manufacturers (2019-2024)
2.4 Global Herceptin Biosimilar Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Herceptin Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Herceptin Biosimilar, Product Type & Application
2.7 Herceptin Biosimilar Market Competitive Situation and Trends
2.7.1 Herceptin Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Herceptin Biosimilar Players Market Share by Revenue
2.7.3 Global Herceptin Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Herceptin Biosimilar Retrospective Market Scenario by Region
3.1 Global Herceptin Biosimilar Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Herceptin Biosimilar Global Herceptin Biosimilar Sales by Region: 2019-2030
3.2.1 Global Herceptin Biosimilar Sales by Region: 2019-2024
3.2.2 Global Herceptin Biosimilar Sales by Region: 2025-2030
3.3 Global Herceptin Biosimilar Global Herceptin Biosimilar Revenue by Region: 2019-2030
3.3.1 Global Herceptin Biosimilar Revenue by Region: 2019-2024
3.3.2 Global Herceptin Biosimilar Revenue by Region: 2025-2030
3.4 North America Herceptin Biosimilar Market Facts & Figures by Country
3.4.1 North America Herceptin Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Herceptin Biosimilar Sales by Country (2019-2030)
3.4.3 North America Herceptin Biosimilar Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Herceptin Biosimilar Market Facts & Figures by Country
3.5.1 Europe Herceptin Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Herceptin Biosimilar Sales by Country (2019-2030)
3.5.3 Europe Herceptin Biosimilar Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Herceptin Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Herceptin Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Herceptin Biosimilar Sales by Country (2019-2030)
3.6.3 Asia Pacific Herceptin Biosimilar Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Herceptin Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Herceptin Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Herceptin Biosimilar Sales by Country (2019-2030)
3.7.3 Latin America Herceptin Biosimilar Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Herceptin Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Herceptin Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Herceptin Biosimilar Sales by Country (2019-2030)
3.8.3 Middle East and Africa Herceptin Biosimilar Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Herceptin Biosimilar Sales by Type (2019-2030)
4.1.1 Global Herceptin Biosimilar Sales by Type (2019-2024)
4.1.2 Global Herceptin Biosimilar Sales by Type (2025-2030)
4.1.3 Global Herceptin Biosimilar Sales Market Share by Type (2019-2030)
4.2 Global Herceptin Biosimilar Revenue by Type (2019-2030)
4.2.1 Global Herceptin Biosimilar Revenue by Type (2019-2024)
4.2.2 Global Herceptin Biosimilar Revenue by Type (2025-2030)
4.2.3 Global Herceptin Biosimilar Revenue Market Share by Type (2019-2030)
4.3 Global Herceptin Biosimilar Price by Type (2019-2030)
5 Segment by Application
5.1 Global Herceptin Biosimilar Sales by Application (2019-2030)
5.1.1 Global Herceptin Biosimilar Sales by Application (2019-2024)
5.1.2 Global Herceptin Biosimilar Sales by Application (2025-2030)
5.1.3 Global Herceptin Biosimilar Sales Market Share by Application (2019-2030)
5.2 Global Herceptin Biosimilar Revenue by Application (2019-2030)
5.2.1 Global Herceptin Biosimilar Revenue by Application (2019-2024)
5.2.2 Global Herceptin Biosimilar Revenue by Application (2025-2030)
5.2.3 Global Herceptin Biosimilar Revenue Market Share by Application (2019-2030)
5.3 Global Herceptin Biosimilar Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Herceptin Biosimilar Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AryoGen Biopharma
6.2.1 AryoGen Biopharma Corporation Information
6.2.2 AryoGen Biopharma Description and Business Overview
6.2.3 AryoGen Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AryoGen Biopharma Herceptin Biosimilar Product Portfolio
6.2.5 AryoGen Biopharma Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocon Herceptin Biosimilar Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Celltrion
6.4.1 Celltrion Corporation Information
6.4.2 Celltrion Description and Business Overview
6.4.3 Celltrion Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celltrion Herceptin Biosimilar Product Portfolio
6.4.5 Celltrion Recent Developments/Updates
6.5 Gedeon Richter
6.5.1 Gedeon Richter Corporation Information
6.5.2 Gedeon Richter Description and Business Overview
6.5.3 Gedeon Richter Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Gedeon Richter Herceptin Biosimilar Product Portfolio
6.5.5 Gedeon Richter Recent Developments/Updates
6.6 Genor Biopharma
6.6.1 Genor Biopharma Corporation Information
6.6.2 Genor Biopharma Description and Business Overview
6.6.3 Genor Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Genor Biopharma Herceptin Biosimilar Product Portfolio
6.6.5 Genor Biopharma Recent Developments/Updates
6.7 Mabion
6.6.1 Mabion Corporation Information
6.6.2 Mabion Description and Business Overview
6.6.3 Mabion Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mabion Herceptin Biosimilar Product Portfolio
6.7.5 Mabion Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mylan Herceptin Biosimilar Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Roche
6.9.1 Roche Corporation Information
6.9.2 Roche Description and Business Overview
6.9.3 Roche Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Roche Herceptin Biosimilar Product Portfolio
6.9.5 Roche Recent Developments/Updates
6.10 The Instituto Vital Brazil
6.10.1 The Instituto Vital Brazil Corporation Information
6.10.2 The Instituto Vital Brazil Description and Business Overview
6.10.3 The Instituto Vital Brazil Herceptin Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.10.4 The Instituto Vital Brazil Herceptin Biosimilar Product Portfolio
6.10.5 The Instituto Vital Brazil Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Herceptin Biosimilar Industry Chain Analysis
7.2 Herceptin Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Herceptin Biosimilar Production Mode & Process
7.4 Herceptin Biosimilar Sales and Marketing
7.4.1 Herceptin Biosimilar Sales Channels
7.4.2 Herceptin Biosimilar Distributors
7.5 Herceptin Biosimilar Customers
8 Herceptin Biosimilar Market Dynamics
8.1 Herceptin Biosimilar Industry Trends
8.2 Herceptin Biosimilar Market Drivers
8.3 Herceptin Biosimilar Market Challenges
8.4 Herceptin Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
